Reviewing Organigram Global (NASDAQ:OGI) and Avita Medical (NASDAQ:RCEL)

Avita Medical (NASDAQ:RCEL) and Organigram Global (NASDAQ:OGI) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, profitability and risk.

Profitability

This table compares Avita Medical and Organigram Global’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Avita Medical	-56.96%	N/A	-78.53%
Organigram Global	28.14%	-13.39%	-8.67%

Analyst Ratings

This is a summary of recent recommendations and price targets for Avita Medical and Organigram Global, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avita Medical	1	1	5	0	2.57
Organigram Global	0	1	2	0	2.67

Avita Medical presently has a consensus price target of $11.40, indicating a potential downside of 13.70%. Given Avita Medical’s higher possible upside, analysts plainly believe Avita Medical is more favorable than Organigram Global.

Earnings & Valuation

This table compares Avita Medical and Organigram Global”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avita Medical	$71.61 million	5.68	-$48.59 million	($1.44)	-9.17
Organigram Global	$185.07 million	0.73	-$17.70 million	$0.46	2.09

Organigram Global has higher revenue and earnings than Avita Medical. Avita Medical is trading at a lower price-to-earnings ratio than Organigram Global, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

27.7% of Avita Medical shares are owned by institutional investors. Comparatively, 34.6% of Organigram Global shares are owned by institutional investors. 2.2% of Avita Medical shares are owned by insiders. Comparatively, 0.1% of Organigram Global shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Volatility & Risk

Avita Medical has a beta of 1.99, indicating that its share price is 99% more volatile than the S&P 500. Comparatively, Organigram Global has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500.

Summary

Organigram Global beats Avita Medical on 8 of the 14 factors compared between the two stocks.

About Avita Medical

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.

About Organigram Global

Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.